Sunesis Pharmaceuticals (SNSS) : Traders are bullish on Sunesis Pharmaceuticals (SNSS) as it has outperformed the S&P 500 by a wide margin of 63.34% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 36.71%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 36.67% in the last 1 week, and is up 63.97% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Sunesis Pharmaceuticals, Inc. is up 72.52% in the last 3-month period. Year-to-Date the stock performance stands at -8.64%. The stock has recorded a 20-day Moving Average of 30.59% and the 50-Day Moving Average is 43.4%.
Sunesis Pharmaceuticals (NASDAQ:SNSS): The stock was completely flat for the day, closing at $0.82 on Friday. The flat closing masks the intraday volatility in the stock. After opening at $0.82, the stock touched an intraday high of $0.84 and a low of $0.73. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $0.82. The total trading volume on Friday was 868,139.
Also, Brokerage firm Wells Fargo upgrades its rating on Sunesis Pharmaceuticals (NASDAQ:SNSS). The shares have been rated Outperform. Previously, the analysts had a Market Perform rating on the shares. The rating by the firm was issued on July 29, 2016.
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Companys program is QINPREZOTM (vosaroxin), which is its product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD), which is a class of compounds that has not been used previously for the treatment of cancer. Vosaroxin is an AQD, which is used for the treatment of cancer. MLN2480 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Brutons tyrosine kinase (BTK). PDK1 is a kinase and mediator of PI3K/AKT signaling, which is a pathway involved in cell growth, differentiation, survival and migration.